{"id":13826,"date":"2026-04-02T11:50:32","date_gmt":"2026-04-02T11:50:32","guid":{"rendered":"https:\/\/www.1stopasia.com\/blog\/?p=13826"},"modified":"2026-04-02T08:16:58","modified_gmt":"2026-04-02T08:16:58","slug":"life-sciences-localization-growth-vendors-selection-criteria","status":"publish","type":"post","link":"https:\/\/www.1stopasia.com\/blog\/life-sciences-localization-growth-vendors-selection-criteria\/","title":{"rendered":"Why Life Sciences localization grew 147% in six months and what it means for your vendor selection"},"content":{"rendered":"

AI Overview<\/h2>\n
\n\n\n\n\n\n\n\n\n
Category<\/strong><\/td>\nSummary<\/strong><\/td>\n<\/tr>\n
Topic<\/strong><\/td>\nThe shift from volume-based to compliance-grade Life Sciences localization and the required update to vendor evaluation criteria<\/td>\n<\/tr>\n
Purpose<\/strong><\/td>\nTo guide LSP vendor managers on updating their evaluation frameworks to ensure compliance for regulated Life Sciences localization, especially for Asian languages.<\/td>\n<\/tr>\n
Key Insight<\/strong><\/td>\nThe 147% growth in Life Sciences localization is a compliance signal (IVDR\/MDR, SaMD) that requires vendors to move beyond the TEP model to systems that ensure LSO capacity, ICR arbitration, and full traceability\/defensibility.<\/td>\n<\/tr>\n
Best Use Case<\/strong><\/td>\nLSP vendor managers and localization directors revising their vendor evaluation frameworks for regulated Asian language Life Sciences content.<\/td>\n<\/tr>\n
Risk Warning<\/strong><\/td>\nRelying on traditional TEP models and outdated vendor criteria (ISO, cost, speed) introduces compliance risk that will only surface during regulatory submission or audit.<\/td>\n<\/tr>\n
Pro Tip<\/strong><\/td>\nImmediately update your vendor evaluation framework to include five operational questions designed to test a partner\u2019s LSO capacity, ICR arbitration workflow, and subject-matter accountability.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\n
Download Article<\/a><\/div>\n
<\/div>\n<\/div>\n

The 147% surge in life sciences translation over the past six months is a structural shift, and if you\u2019re responsible for vendor selection, it\u2019s a warning signal.<\/p>\n

This spike, highlighted in The State of Language Operations Outsourcing 2025\/2026<\/a> Report, wasn\u2019t driven by more content in the traditional sense. It came from compliance pressure. Specifically, regulatory frameworks like IVDR, MDR, and the continued expansion of software as a medical device (SaMD) requirements have fundamentally changed what \u201cdone\u201d looks like in Life Sciences localization.<\/p>\n

For procurement teams, that means one thing: the vendor criteria that worked even 12-18 months ago are no longer sufficient.<\/p>\n

This article breaks down what actually changed and how to adjust your medical translation vendor selection process before those gaps show up in an audit.<\/p>\n

The 147% growth is a compliance signal\u00a0<\/h2>\n

At first glance, a 147% increase in life sciences translation volume looks like a scaling problem. More markets, more content, more languages. That\u2019s the familiar story. But that\u2019s not what the data shows.<\/p>\n

The growth is tied directly to regulatory expansion, particularly IVDR\/MDR localization requirements in Europe and parallel compliance pressures across Asian markets. The increase isn\u2019t coming from marketing content or IFU updates alone. It\u2019s coming from:<\/p>\n